Form D · Biotechnology
Traws Pharma, Inc.
Newtown, PA · CIK 0001130598
Offering snapshot reported Nov 5, 2026 · SEC filing
- Reported sold
- Yet to sell Offering amount: $50M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Yet to occur As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Nov 5, 2026 | Initial | Yet to sell | No comparison | 1 | SEC filing |
| Apr 16, 2024 | Initial | $14,000,000 | No comparison | 2 | SEC filing |
| Jun 4, 2019 | Initial | $500,000 | No comparison | 1 | SEC filing |
| Jun 8, 2018 | Initial | $1,250,000 | No comparison | 1 | SEC filing |
| Oct 23, 2015 | Initial | $1,500,000 | No comparison | 1 | SEC filing |
| Aug 13, 2012 | Initial | $49,999,999 | No comparison | 1 | SEC filing |
| Jul 26, 2012 | Amendment | $26,444,316 | $19,394,316vs May 10, 2012 | 41 | SEC filing |
| May 10, 2012 | Initial | $7,050,000 | No comparison | 4 | SEC filing |
| Jan 5, 2011 | Amendment | $11,690,190 | $5,144,577vs Oct 4, 2010 | 67 | SEC filing |
| Oct 4, 2010 | Initial | $6,545,613 | No comparison | 32 | SEC filing |
| Mar 4, 2010 | Amendment | $19,226,287 | $13,965,514vs May 26, 2009 | 58 | SEC filing |
| May 26, 2009 | Initial | $5,260,773 | No comparison | Not reported | SEC filing |
| May 30, 2007 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Apr 1, 2005 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- Yes
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-603794
Offering is a committed equity facility under which the issuer has the right, in its sole discretion, to sell to the investor up to an aggregate of $50,000,000 of the issuer's common stock from time to time, subject to certain limitations.
Source: Form D, filed Nov 5, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Ajay Bansal | Executive |
| Henry S. Bienen | Director |
| Henry S. Bienen, Ph.D. | Director |
| Henry B. Binen | Director |
| Werner Cautreels | Director |
| Trafford Clarke | Director |
| Ian Dukes | Director |
| Iain Dukes | Director, Executive |
| Steven Fruchtman | Executive |
| Jerome E. Groopman | Director |
| Mark Guerin | Executive |
| Michael B. Hoffman | Director |
| Ramesh Kumar | Director, Executive |
| Ramesh Kumar, Ph.D | Director, Executive |
| Ramesh Kumar, Ph.D. | Director, Executive |
| Shekhar Kundur | Director |
| John Leaman | Director |
| Manoj Maniar | Executive |
| James Marino | Director |
| Thomas Mc Kearn | Executive |
| Viren Mehta | Director |
| Abraham N. Oler | Executive |
| Charles Parker | Executive |
| Pankaj Patel | Director |
| David Pauza | Executive |
| K. Ravindra | Director |
| K Ravindra | Director |
| Premkumar Reddy | Director |
| E. Premkumar Reddy | Director |
| E. Premkumar Reddy, Ph.D | Director, Executive |
| E. Premkumar Reddy, Ph.D. | Director, Executive |
| Robert Redfield | Executive |
| Nikolay Savchuk | Director |
| M. Theresa Shoemaker | Director |
| Mary Teresa Shoemaker | Director |
| Jack E. Stover | Director |
| Anne M. Van Lent | Director |
| Alan R. Williamson | Director |
| Richard C. Woodman | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
12 Penns Trail
Newtown, PA, 18940
Newtown, PA, 18940